A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal CancerThomas Powles, Christy Ralph, Santhanam Sundar et al.|European Urology|2015Cited by 100
The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal CancerKevin Sharpe, Tom Powles, Grant D. Stewart et al.|Clinical Cancer Research|2013Cited by 69
A randomized phase II study of AZ2014 versus everolimus in patients with VEGF refractory metastatic clear cell renal cancer (mRCC).Thomas Powles, Christy Ralph, Matthew Wheater et al.|Journal of Clinical Oncology|2015Cited by 5